{"title":"Case Report: Allelic and biallelic variants in <i>coagulation factor XI</i> cause factor XI deficiency.","authors":"Chen Liang, Jie-Yuan Jin, Hai-Hong Shi, Hao-Xian Li, Lin-Lin Chen, Yang-Hui Zhang, Qin Wang, Qiu-Li Li, Rui-Man Li","doi":"10.3389/fcvm.2024.1461899","DOIUrl":null,"url":null,"abstract":"<p><p>Factor XI deficiency is a rare inherited coagulation disorder with an estimated prevalence of affecting 1 in 1 million. It is characterized by mild and variable bleeding phenotypes, including bruises, nosebleeds, hematuria, and postpartum hemorrhage. It can be caused by either allelic or biallelic variants in <i>coagulation factor XI</i> (<i>F11</i>). Coagulation factor XI is a glycoprotein that circulates in plasma as a non-covalent complex with high-molecular-weight kininogen. It is converted to an active protease, coagulation factor XIa, which participates in blood coagulation as a catalyst. In this study, we recruited a family with Factor XI deficiency and identified two <i>F11</i> variants using whole-exome sequencing. One (NM_000128.4: c.841C>T, p.Q281X) was a known variant, and the other (NM_000128.4: c.1832T>G, p.V611G) had not been reported. In addition, we compiled the characteristics of known missense variants in <i>coagulation factor XI</i>. Our findings enriched the variant spectrum of Factor XI deficiency and contributed to the genetic counseling and molecular diagnostics of Factor XI deficiency.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1461899"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599221/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2024.1461899","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Factor XI deficiency is a rare inherited coagulation disorder with an estimated prevalence of affecting 1 in 1 million. It is characterized by mild and variable bleeding phenotypes, including bruises, nosebleeds, hematuria, and postpartum hemorrhage. It can be caused by either allelic or biallelic variants in coagulation factor XI (F11). Coagulation factor XI is a glycoprotein that circulates in plasma as a non-covalent complex with high-molecular-weight kininogen. It is converted to an active protease, coagulation factor XIa, which participates in blood coagulation as a catalyst. In this study, we recruited a family with Factor XI deficiency and identified two F11 variants using whole-exome sequencing. One (NM_000128.4: c.841C>T, p.Q281X) was a known variant, and the other (NM_000128.4: c.1832T>G, p.V611G) had not been reported. In addition, we compiled the characteristics of known missense variants in coagulation factor XI. Our findings enriched the variant spectrum of Factor XI deficiency and contributed to the genetic counseling and molecular diagnostics of Factor XI deficiency.
因子 XI 缺乏症是一种罕见的遗传性凝血障碍,估计发病率为百万分之一。其特征是轻度和多变的出血表型,包括瘀伤、鼻出血、血尿和产后出血。它可由凝血因子 XI(F11)的等位基因变异或双等位基因变异引起。凝血因子 XI 是一种糖蛋白,以与高分子量激肽原形成非共价复合物的形式在血浆中循环。它可转化为一种活性蛋白酶--凝血因子 XIa,作为催化剂参与血液凝固。在这项研究中,我们招募了一个因子 XI 缺乏症家族,并通过全外显子组测序鉴定出了两个 F11 变体。其中一个(NM_000128.4:c.841C>T,p.Q281X)是已知变异,另一个(NM_000128.4:c.1832T>G,p.V611G)则未见报道。此外,我们还汇编了凝血因子 XI 中已知错义变异的特征。我们的研究结果丰富了因子 XI 缺乏症的变异谱,有助于因子 XI 缺乏症的遗传咨询和分子诊断。
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.